Your browser is no longer supported. Please, upgrade your browser.
Settings
APVO Aptevo Therapeutics Inc. daily Stock Chart
APVO [NASD]
Aptevo Therapeutics Inc.
Index- P/E- EPS (ttm)-2.21 Insider Own1.70% Shs Outstand22.11M Perf Week1.26%
Market Cap35.60M Forward P/E- EPS next Y-2.10 Insider Trans4.16% Shs Float17.56M Perf Month-1.83%
Income-49.40M PEG- EPS next Q-0.54 Inst Own32.90% Short Float0.92% Perf Quarter-62.99%
Sales19.50M P/S1.83 EPS this Y74.20% Inst Trans-0.14% Short Ratio1.57 Perf Half Y-67.41%
Book/sh1.94 P/B0.83 EPS next Y9.10% ROA-51.10% Target Price9.50 Perf Year-51.80%
Cash/sh1.70 P/C0.95 EPS next 5Y- ROE-78.80% 52W Range1.11 - 6.35 Perf YTD26.77%
Dividend- P/FCF- EPS past 5Y7.10% ROI-30.40% 52W High-75.28% Beta-
Dividend %- Quick Ratio3.70 Sales past 5Y30.10% Gross Margin55.70% 52W Low41.44% ATR0.13
Employees121 Current Ratio3.90 Sales Q/Q-6.50% Oper. Margin- RSI (14)41.92 Volatility5.47% 8.78%
OptionableYes Debt/Eq0.43 EPS Q/Q-503.60% Profit Margin- Rel Volume0.82 Prev Close1.61
ShortableYes LT Debt/Eq0.43 EarningsNov 15 Payout- Avg Volume102.74K Price1.57
Recom1.70 SMA206.73% SMA50-25.57% SMA200-61.71% Volume5,425 Change-2.48%
Nov-05-18Initiated Ladenburg Thalmann Buy
Oct-05-17Resumed Piper Jaffray Overweight $6
Jan-07-19 08:30AM  Aptevo Therapeutics Highlights Key 2019 Priorities GlobeNewswire
Jan-03-19 09:02AM  Aptevo Therapeutics Collects $3.3 Million In Escrow Funds From Saol Therapeutics GlobeNewswire
Dec-21-18 09:00AM  Aptevo Therapeutics Announces Up To $35 Million Common Stock Purchase Agreement With Lincoln Park Capital GlobeNewswire -9.29%
Dec-20-18 12:57PM  Need To Know: Aptevo Therapeutics Inc. (NASDAQ:APVO) Insiders Have Been Buying Shares Simply Wall St. -11.95%
Dec-13-18 09:02AM  Aptevo Therapeutics Doses First Patient in Phase 1/1b Clinical Trial of Lead Next-Generation Bispecific Antibody APVO436 GlobeNewswire -6.98%
Dec-11-18 07:20AM  United Parcel Service, Endurance International Group, Idera Pharmaceuticals, Aptevo Therapeutics, and Electro Scientific Industries Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-20-18 09:00AM  Aptevo Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-14-18 04:02PM  Aptevo Therapeutics Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-09-18 12:00AM  Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting GlobeNewswire -5.88%
Oct-24-18 09:00AM  Aptevo Therapeutics Announces Expanded Growth Initiatives for IXINITY GlobeNewswire -12.88%
Oct-10-18 08:40AM  Market Trends Toward New Normal in Aptevo Therapeutics, Bottomline Technologies, Allete, Air Lease, The Goodyear Tire & Rubber, and EastGroup Properties Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Sep-25-18 11:29AM  Aptevo Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference GlobeNewswire
Sep-05-18 11:36AM  Here's Why Momentum Investors Will Love Aptevo Therapeutics Inc. (APVO) Zacks
Aug-31-18 02:46PM  Penny Stocks to Buy Using Technical Analysis for September 2018 Investopedia
Aug-09-18 09:00AM  Aptevo Therapeutics Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-07-18 09:00AM  Aptevo Therapeutics Revises Term Loan Agreement With MidCap Financial; Reduces Cash Requirements by $18 Million GlobeNewswire
Aug-06-18 08:10AM  Report: Developing Opportunities within athenahealth, W.R. Berkley, Air Products and Chemicals, DICK'S Sporting Goods, Aptevo Therapeutics, and Columbia Property Trust Future Expectations, Projections Moving into 2018 GlobeNewswire
May-29-18 09:00AM  Novel First-In-Class Immunotherapeutic APVO210 Features Unique Mechanism of Action Delivering IL-10 GlobeNewswire
May-15-18 07:40AM  Wired News Arrowhead Pharma Presented Preclinical Data on Expanding Pipeline of RNAi Therapeutics for Cardiometabolic Diseases ACCESSWIRE +17.10%
May-10-18 09:00AM  Aptevo Therapeutics Reports First Quarter 2018 Financial Results GlobeNewswire +14.22%
May-08-18 09:02AM  New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 Presented by Aptevo Therapeutics and Alligator Bioscience at Prominent Industry Conferences GlobeNewswire
May-01-18 09:00AM  Aptevo Therapeutics Announces IND Submission for APVO436 GlobeNewswire
Apr-30-18 07:50AM  Report: Developing Opportunities within Natus Medical, Aptevo Therapeutics, Revlon, Silgan, Resources Connection, and TrustCo Bank Corp NY Future Expectations, Projections Moving into 2018 GlobeNewswire
Apr-20-18 08:35PM  Aptevo executive Jane Gross jumped to a startup and landed in the C-Suite American City Business Journals
Apr-16-18 09:02AM  Aptevo Therapeutics Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release GlobeNewswire +17.99%
Mar-19-18 08:20AM  Research Report Identifies Ambarella, Merit Medical, NETGEAR, Independent Bank, Cutera, and Aptevo Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-13-18 09:02AM  Aptevo Therapeutics Reports 2017 Financial Results and Provides Business Update GlobeNewswire
Mar-12-18 09:02AM  Aptevo Therapeutics Presents New Patient-Reported Data With IXINITY GlobeNewswire
Feb-27-18 09:02AM  Aptevo Therapeutics to Present at the 30th Annual ROTH Conference GlobeNewswire
Jan-17-18 08:10AM  Report: Exploring Fundamental Drivers Behind Anthera Pharmaceuticals, Alarm, Aptevo Therapeutics, Shoe Carnival, Independent Bank, and First Internet New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire +10.02%
Jan-11-18 09:04AM  How Is Bioverativs Alprolix Positioned Now? Market Realist
Jan-08-18 09:00AM  Aptevo Therapeutics Begins Patient Dosing in Phase 2 Clinical Trial of Otlertuzumab in Peripheral T-Cell Lymphoma GlobeNewswire -8.55%
Jan-03-18 08:17AM  Aptevo Therapeutics, Inc. :APVO-US: Earnings Analysis: Q3, 2017 By the Numbers : January 3, 2018 Capital Cube
Dec-27-17 10:58AM  ETFs with exposure to Aptevo Therapeutics, Inc. : December 27, 2017 Capital Cube
Dec-19-17 09:05AM  Does Aptevo Therapeutics Incs (NASDAQ:APVO) 74.9% EPS Growth Reflect The Long-Term Trend? Simply Wall St.
Dec-11-17 01:28PM  ETFs with exposure to Aptevo Therapeutics, Inc. : December 11, 2017 Capital Cube -5.67%
09:02AM  Aptevo Therapeutics Novel Bispecific Antibody Therapeutic APVO436 Shows Broad Activity in Primary Human AML Samples GlobeNewswire
Nov-29-17 10:58AM  ETFs with exposure to Aptevo Therapeutics, Inc. : November 29, 2017 Capital Cube
Nov-28-17 07:02AM  Aptevo Therapeutics Announces Plans to Conduct Phase 2 Study of Otlertuzumab in Peripheral T-Cell Lymphoma GlobeNewswire
Nov-21-17 06:39PM  Is Aptevo Therapeutics Incs (APVO) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Nov-14-17 04:02PM  Aptevo Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-09-17 04:30PM  Aptevo Therapeutics Reports Third Quarter 2017 Financial Results GlobeNewswire +6.29%
Nov-01-17 11:50AM  ETFs with exposure to Aptevo Therapeutics, Inc. : November 1, 2017 Capital Cube
Oct-30-17 09:02AM  Aptevo Therapeutics Presents New Preclinical Data on APVO436 a Next Generation ADAPTIR Bispecific Antibody Candidate GlobeNewswire -5.40%
Oct-24-17 09:00AM  Tumor Antigen 5T4 Associated With Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527 a Novel Bispecific Antibody Candidate Being Developed by Alligator Bioscience and Aptevo Therapeutics GlobeNewswire +5.19%
Oct-16-17 09:02AM  Aptevo Therapeutics Showcases New Mechanism of Action for Its ADAPTIR Platform at the Inflammation Research Society Meeting GlobeNewswire -6.17%
Oct-10-17 08:31AM  Aptevo Therapeutics, Analyst Coverage, ADAPTIR Platform and Recent Drug Asset Sale ACCESSWIRE
Oct-06-17 10:37AM  ETFs with exposure to Aptevo Therapeutics, Inc. : October 6, 2017 Capital Cube
Oct-02-17 09:00AM  Aptevo Therapeutics Presents New Data on Enhanced Features of Its Next Generation ADAPTIR Bispecific Platform at the World Bispecific Summit GlobeNewswire
Sep-28-17 04:45PM  Aptevo Therapeutics Extends Cash Runway $20 Million; Retains Term Loan Agreement With MidCap Financial GlobeNewswire
04:35PM  Aptevo Therapeutics Completes Sale of Hyperimmune Products for Up to $74.5 Million GlobeNewswire
Aug-31-17 05:17PM  ETFs with exposure to Aptevo Therapeutics, Inc. : August 31, 2017 Capital Cube +5.56%
05:16PM  Aptevo Therapeutics Signs Agreement for Up to $74.5 Million to Sell Hyperimmune Commercial Products GlobeNewswire
05:15PM  Aptevo Therapeutics and MorphoSys End Joint Development and Commercialization Agreement for MOR209/ES414 GlobeNewswire
Aug-25-17 11:29AM  Aptevo Therapeutics, Inc. :APVO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Capital Cube -5.22%
Aug-17-17 07:00AM  Aptevo Therapeutics and Alligator Bioscience Commence IND-Enabling Development Activities for New Bispecific Immunotherapy Candidate ALG.APV-527 GlobeNewswire
Aug-10-17 09:02AM  Aptevo Therapeutics Reports Second Quarter 2017 Financial Results GlobeNewswire +8.02%
Aug-01-17 04:12PM  ETFs with exposure to Aptevo Therapeutics, Inc. : August 1, 2017 Capital Cube
Jul-20-17 05:20PM  Aptevo Therapeutics and Alligator Bioscience Announce Plans to Co-Develop Novel Bispecific Antibody for Tumor-Directed Immunotherapy GlobeNewswire
03:10PM  Emergent BioSolutions acquires GlaxoSmithKline anthrax drug for $96 million American City Business Journals
Jul-07-17 02:27PM  ETFs with exposure to Aptevo Therapeutics, Inc. : July 7, 2017 Capital Cube
Jun-07-17 09:02AM  Aptevo Therapeutics Highlights Key Features of Its ADAPTIR Protein Therapeutic Platform at Two Industry Conferences GlobeNewswire
Jun-05-17 02:00PM  ETFs with exposure to Aptevo Therapeutics, Inc. : June 5, 2017 Capital Cube -7.87%
Jun-02-17 10:32AM  Aptevo Therapeutics, Inc. :APVO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-12-17 09:02AM  Aptevo Therapeutics Reports First Quarter 2017 Financial Results GlobeNewswire
May-05-17 09:02AM  Aptevo Therapeutics Presents Detailed Overview of its Adaptir Protein Therapeutic Platform at the 13th Annual Pegs Summit GlobeNewswire
Apr-28-17 03:40PM  ETFs with exposure to Aptevo Therapeutics, Inc. : April 28, 2017 Capital Cube
Apr-10-17 01:41PM  ETFs with exposure to Aptevo Therapeutics, Inc. : April 10, 2017 Capital Cube
09:00AM  Aptevo Therapeutics Presents New Clinical Data Evaluating the Safety and Efficacy of IXINITY in Children With Hemophilia B GlobeNewswire
Apr-07-17 02:58PM  Aptevo Therapeutics, Inc. :APVO-US: Earnings Analysis: Q4, 2016 By the Numbers : April 7, 2017 Capital Cube
12:28PM  Aptevo Therapeutics, Inc. :APVO-US: Earnings Analysis: 2016 By the Numbers : April 7, 2017 Capital Cube
Apr-03-17 09:03AM  Aptevo Therapeutics Next Generation ADAPTIR Bispecific Antibody Candidates Show Potent Immune Activation GlobeNewswire
Mar-31-17 09:42AM  APTEVO THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Non-Reliance on Previous +5.10%
09:00AM  Aptevo Therapeutics Reports 2016 Financial Results and Provides Business Update GlobeNewswire
Mar-15-17 08:30AM  Aptevo Therapeutics Announces New IXINITY Supply Available May 2017 GlobeNewswire -5.53%
Mar-14-17 09:25AM  Aptevo Therapeutics Expands Bispecific Antibody Portfolio GlobeNewswire +9.34%
Mar-06-17 08:30AM  Aptevo Therapeutics to Present at the 29th Annual ROTH Conference GlobeNewswire
Feb-24-17 06:31PM  Emergent BioSolutions Inc Sets its Goal Motley Fool
06:31PM  Emergent BioSolutions Inc Sets its Goal at Motley Fool
04:54PM  APTEVO THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers
Feb-16-17 01:34PM  These 5 Stocks Under $10 Could Explode Higher +14.87%
Jan-13-17 09:02AM  Aptevo Therapeutics Receives $20 Million Payment From Emergent BioSolutions GlobeNewswire
Jan-12-17 09:02AM  Aptevo Therapeutics Presents Data on Its ADAPTIR Antibody Platform at the 16th Annual PEPTALK Conference GlobeNewswire
Jan-10-17 02:40PM  Emergent Down on '17 View, Posts Preliminary '16 Results Zacks
Jan-09-17 06:05AM  APTEVO THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibit
Jan-04-17 07:58AM  Aptevo Therapeutics Resumes IXINITY Manufacturing; Anticipates Re-Entering the Market in the Second Quarter of 2017 GlobeNewswire
Dec-19-16 11:58PM  How Aptevo Therapeutics Inc (APVO) Stacks Up Against Its Peers at Insider Monkey
Dec-16-16 09:05AM  Aptevo Therapeutics Announces Publication of Phase 2 Clinical Data for Otlertuzumab GlobeNewswire
Dec-15-16 01:55PM  Aptevo Therapeutics Amends Collaboration Agreement with MorphoSys AG for Novel Immunotherapeutic, MOR209/ES414 GlobeNewswire
01:52PM  APTEVO THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exh
Nov-28-16 04:32PM  APTEVO THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Nov-23-16 09:03AM  Aptevo Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-14-16 05:51PM  APTEVO THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report
Nov-10-16 02:45PM  Emergent Biosolutions Inc Slimmed Down, Waiting on Contract at Motley Fool
Nov-08-16 08:07AM  Emergent (EBS) Beats Earnings & Revenue Estimates in Q3
Sep-22-16 11:51AM  APTEVO THERAPEUTICS INC. Files SEC form 10-Q/A, Quarterly Report
Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. The company's marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals. Its investigational stage product candidates include MOR209/ES414, a bispecific immunotherapeutic protein that is in Phase I clinical trial for metastatic castration-resistant prostate cancer; ES210, a bispecific protein therapeutic that is in pre-clinical development stage for inflammatory bowel diseases; otlertuzumab, a monospecific protein therapeutic that is in Phase II clinical trial for chronic lymphocytic leukemia; ROR1, a bispecific immunotherapeutic protein that is in preclinical development; APVO436, a bispecific protein therapeutic, which is in pre-clinical development; and other therapeutic protein product candidates for cancer. The company was incorporated in 2016 and is based in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Maddux Randy JoeSVP OperationsDec 06Buy2.375,00011,85030,000Dec 07 06:28 PM
White Marvin LPresident and CEODec 04Buy2.3810,00023,800203,603Dec 06 10:23 AM